Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ProBioGen and Emergent BioSolutions Partner

Published: Tuesday, December 17, 2013
Last Updated: Tuesday, December 17, 2013
Bookmark and Share
ProBioGen announces expansion of commercial licenses with Emergent BioSolutions for AGE1.CR® viral vaccine manufacturing production platform.

ProBioGen announced that it has signed an agreement with Emergent BioSolutions for a non-exclusive commercial multi-product license and option agreement under which Emergent will be granted broad access to ProBioGen’s avian AGE1.CR® cell line.

Previously, ProBioGen had granted an exclusive license to Emergent for four indications and also conducted process development work for Emergent. As a result of the new agreement, ProBioGen’s relationship with Emergent is now extended to include additional infectious disease targets, with the option to expand to numerous further indications. The commercial licenses include milestones and royalty payments. Financial details were not disclosed.

Volker Sandig, Chief Scientific Officer noted: “Innovative medicines against infectious diseases are urgently needed. We are convinced that the combination of ProBioGen’s AGE1.CR® cell line for production of MVA-based vaccines together with Emergent’s product development, manufacturing and marketing expertise will yield novel preventive and therapeutic products."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ProBioGen in Biosimilar Deal with Bio Farma Indonesia
Trastuzumab development and transfer for first indonesian on-site production.
Thursday, October 29, 2015
Anti-Ebola MVA Vaccine Produced on Avian AGE1.CR® Cell Line in Clinical Trials
"Production of the first ever batch of MVA for a clinical trial using a cell line".
Wednesday, June 03, 2015
20 Years ProBioGen
Invests €20 million in mammalian manufacturing expansion.
Wednesday, September 10, 2014
ProBioGen Signs GlymaxX ADCC Enhancement Technology License Deal
A non-exclusive commercial multi-product licensing agreement with Novartis.
Tuesday, June 24, 2014
ProBioGen and Merus Sign Deal on GlymaxX® ADCC Enhancement Technology
GlymaxX® manufacturing technology improves bispecific antibody activity for solid tumor treatment.
Wednesday, March 05, 2014
ProBioGen Upholds Strong Patent Position in Viral Vaccine Manufacturing Field
Company offers licenses and contract research services to human and animal vaccine companies.
Thursday, October 31, 2013
ProBioGen Signs Deal with TOP 10 Pharma Company for Therapeutic Antibody Platform
Another global pharma company has licensed ProBioGen’s GlymaxX® ADCC-enhancement technology.
Wednesday, February 20, 2013
Ceva and ProBioGen Signs Multi-product License Agreement
Ceva takes commercial license for ProBioGen’s AGE1.CR® cell line for viral vaccine production.
Friday, March 16, 2012
ProBioGen and Inhibrx Sign License Deal on GlymaxX® ADCC Technology
GlymaxX® ADCC technology and mammalian cell line development and manufacturing services used to advance therapeutic antibodies.
Friday, October 28, 2011
Scientific News
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Anthrax Vaccine Protects Monkeys
Vaccination with the anthrax capsule—a naturally occurring component of the bacterium that causes the disease—completely protected monkeys from lethal anthrax infection, according to a recently published study.
Long-Term Culturing of Adult Stem Cells
A new procedure developed by Harvard Stem Cell Institute researchers (HSCI) at Massachusetts General Hospital (MGH) may revolutionize the culturing of adult stem cells.
Solutions for Biotherapeutic Characterization
Innovation to speed the routine.
Plant-Based Vaccine Among Front Runners In Search For New Polio Jab
A researcher from Norwich is part of a consortium that has been awarded $1.5 million to develop safer polio vaccines, using a new technique developed at the John Innes Centre.
Harnessing Helpful Microbes
Seeking to further harness microbes’ many uses, the federal government has launched the National Microbiome Initiative (NMI) to “foster the integrated study of microbiomes across different ecosystems.”
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
Better Animal Model to Improve HIV Vaccine Development
Penn study identifies a new tool to produce better HIV vaccine designs.
First Large-Scale Proteogenomic Study of Breast Cancer
The study offers understanding of potential therapeutic targets.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!